Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
Lavoie G. et al, (2025), Thorax, 80, 113 - 116
Effects of biologic therapy on novel indices of lung inhomogeneity in patients with severe type-2 high asthma
Alamoudi A. et al, (2025), BMJ Open Respiratory Research, 12, e002721 - e002721
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment.
Lavoie G. et al, (2024), Thorax
The effect of supplemental oxygen and continuous positive airway pressure withdrawal on endocan levels
Turnbull CD. et al, (2024), Sleep and Breathing, 28, 2509 - 2514
Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK
Taquet M. et al, (2024), The Lancet Psychiatry, 11, 696 - 708
Long-term impact of COVID-19 hospitalisation among individuals with pre-existing airway diseases in the UK: a multicentre, longitudinal cohort study - PHOSP-COVID.
Elneima O. et al, (2024), ERJ open research, 10, 982 - 2023
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease
Liew F. et al, (2024), Nature Immunology, 25, 607 - 621
Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.
Bourdin A. et al, (2024), The journal of allergy and clinical immunology. In practice, 12, 809 - 823
Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease
Petousi N. et al, (2024), Thorax
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study
Raman B. et al, (2023), The Lancet Respiratory Medicine, 11, 1003 - 1019
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study
Jackson C. et al, (2023), The Lancet Respiratory Medicine, 11, 673 - 684
Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls
Zheng B. et al, (2023), The Lancet Regional Health - Europe, 29, 100635 - 100635
The Lancet COPD Commission: broader questions remain
Petousi N. et al, (2023), The Lancet, 401, 1569 - 1570
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study
McAuley HJC. et al, (2023), eClinicalMedicine, 57, 101896 - 101896
Persistence of inflammatory and vascular mediators 5 months after hospitalization with COVID-19 infection
Melhorn J. et al, (2023), Frontiers in Medicine, 10
Toward a Predict and Prevent Approach in Obstructive Airway Diseases.
Couillard S. et al, (2023), J Allergy Clin Immunol Pract
Editorial: Physiological phenotyping in respiratory diseases: New approaches.
King GG. et al, (2023), Frontiers in physiology, 14
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Liew F. et al, (2023), eBioMedicine, 87, 104402 - 104402
Altered lung physiology in two cohorts after COVID-19 infection as assessed by computed cardiopulmonography
Magor-Elliott SRM. et al, (2022), Journal of Applied Physiology, 133, 1175 - 1191